Sponsor: Stride Stride helps people understand and improve their wellbeing and longevity through personalized DNA, microbiome, blood biomarker testing, expert guidance, tailored supplements, and actionable insights grounded in robust human science. Click the link below to learn more and use the code 'UNLOCKED' for your 10% discount. Link: https://www.getstride.com/unlocked/ ______________________ In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest breakthroughs shaping healthspan and longevity. From oral GLP-1 pills transforming obesity and metabolic care, to early gene therapy results in aging dogs, and Amazon integrating biomarker-driven longevity insights into primary care, this episode covers innovation, risk, and opportunity across human and animal longevity. Novo Nordisk and Eli Lilly are moving forward with oral versions of their GLP-1 drugs, potentially bringing millions more patients onto treatment. Pills are easier to access than injections, but counterfeiting risks are rising. GLP-1 therapies are evolving beyond weight loss into long-term metabolic health interventions, targeting cardiovascular, joint, and chronic pain outcomes.London-based GenFlow Biosciences released preliminary data from its SERTI6 gene therapy in aged dogs. All treatment groups showed improved survival, muscle mass, and frailty scores. This dual approach addresses companion animal health while acting as a translational model for human aging interventions.In digital health, Amazon One Medical is rolling out biomarker-driven insights powered by LifeForce’s longevity platform. This signals a growing shift in how consumer and clinical longevity data will influence behavior, outcomes, and healthcare delivery.In consumer trends, global PR firm Edelman highlights the rise of the longevity generation. Their Longevity Lab initiative shows that people 55 and older control more than half of global consumer spending, yet receive only a fraction of marketing budgets. Brands are beginning to rethink products, campaigns, and services for older, active, high-spending consumers, a growing business opportunity in the health, finance, hospitality, and lifestyle sectors.Israeli neurotech company QuantalX launched the Delphi MD system in the US, a non-invasive brain function assessment combining transcranial magnetic stimulation, EEG, and AI analytics. Already deploying at Penn, Mass General, UCSF, and UT Dallas, the test has a reimbursement code, potentially shifting brain health monitoring from reactive to preventative care.Gimv, a European investment firm, signaled a pullback from early-stage aging biotech, citing long timelines and unpredictable ROI. Capital is now shifting toward technology-enabled services, diagnostics, and digital longevity platforms where returns are faster and more measurable. ______________________ News & References: What Gimv’s biotech pullback says about aging markets → https://longevity.technology/news/what-gimvs-biotech-pullback-says-about-aging-markets/Are global brands ready for longevity? → https://longevity.technology/news/are-global-brands-ready-for-longevity/New functional brain assessment system rolls out in the US → https://longevity.technology/news/new-functional-brain-assessment-system-rolls-out-in-the-us/As obesity drugs go oral and access grows, so do fakes → https://longevity.technology/news/as-obesity-drugs-go-oral-and-access-grows-so-do-fakes/Genflow reveals early data from SIRT6 gene therapy trial in dogs → https://longevity.technology/news/genflow-reveals-early-data-from-sirt6-gene-therapy-trial-in-dogs/Amazon makes longevity move with Lifeforce collab → https://longevity.technology/news/amazon-makes-longevity-move-with-lifeforce-collab/ ______________________ Hosts: Phil Newman: https://qrco.de/bgXpNY Nina Patrick: https://qrco.de/bgXpKn